Optimizing clotting factor replacement therapy in hemophilia: A global need

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 229-230

  Srivastava, Alok ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE;

BLEEDING; DISEASE SEVERITY; DOSE RESPONSE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HEMARTHROSIS; HEMOPHILIA; HEMOSTASIS; HUMAN; JOINT INJURY; MORBIDITY; MUSCULOSKELETAL INJURY; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SHORT SURVEY; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

BLOOD COAGULATION FACTORS; CLINICAL PROTOCOLS; HEMOPHILIA A; HUMANS; WORLD HEALTH;

EID: 29244471286     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331390320     Document Type: Short Survey

References (7)

1. Srivastava A. Dose and response in haemophilia: Optimization of factor replacement therapy. Br J Haematol 2004;127:12-25.
2. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Int Med 1997;241:395-400.
3. Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, Grobbee DE, Van Den Berg HM. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001;7:446-452.
4. Ljung RC. Prophylactic treatment in Sweden-overtreatment or optimal model? Haemophilia 1998;4:409-412.
5. Van Dijk K, Van Der Bom JG, Bax KN, Van Der Zee DC, Van Den Berg MH. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004 Feb;89:189-194.
6. Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia 2003;9:111-116.
7. Srivastava A. Factor replacement therapy in haemophilia - are there models for developing countries? Haemophilia 2003;9: 391-396.